Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This randomized pilot clinical trial studied whether the Oncotype DX gene expression
"Recurrence Score" (RS) would be useful for helping make a decision about which type of
pre-operative treatment, hormone therapy or chemotherapy would be a better for patients with
hormone responsive cancers that were not suitable for breast conserving surgery. The RS is
currently used to predict the risk of distant recurrence and the benefit of the addition of
chemotherapy to hormonal therapy in the adjuvant setting.